On Aug 19, 2022 Axsome Therapeutics announced the FDA Approval of Auvelity, as the first and Only Oral NMDA Receptor Antagonist for the treatment of Major Depressive Disorder in adults.
(CORRECTION: In the mechanism section, it is SIGMA RECEPTOR AGONISM & NOT ANTAGONISM)
We have summarized this FDAapproved medication in the following
Psychiatry Education Forum Academy Updates:
Read Details: https://psychiatryeducationforum.com/...